Back

Is aspirin the preferred monotherapy after DAPT?

1 September 2024 (13:00 - 13:15)
Organised by: Logo
Congress Presentation Part of: Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions Antiplatelet Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

3 More presentations in this session

Presentation thumbnail
De-escalation vs. early cessation of DAPT for patients at high bleeding risk
Doctor P. Rath (Hyderabad, IN)
Slides Video
Presentation thumbnail
When should we prolong DAPT beyond 12 months?
Doctor M. Das (Kolkata, IN)
Slides Video
Presentation thumbnail
Machine learning to determine the optimal mode and duration of DAPT
Doctor B. Vogel (San Diego, US)
Slides Video

Access the full session

Session thumbnail
Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Do we really need aspirin?
18 March 2022
thumbnail
Congress Presentation
Choice of monotherapy following short duration of dual-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis of randomized clinical trials
31 August 2025
thumbnail
Congress Presentation
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
30 August 2024
thumbnail
Congress Presentation
Antiplatelet monotherapy in acute coronary syndromes: which patients and when
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources